Stock listing

MCRB Stock Price, News, Filings & Events — Seres Therapeutics, Inc.

Selected listing: MCRB · BX · CHF · CH

This page tracks Seres Therapeutics, Inc.'s MCRB:BX listing on BX in CHF for CH, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following MCRB:BX. MCRB:BX is the stock-level entry point for investors researching Seres Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Seres Therapeutics, Inc. is a public company traded under the ticker MCRB in the American market. The company has a market capitalization of approximately $48 million. Seres focuses on developing microbiome-based therapeutics to treat various diseases.

MCRB:BXCHFCHUpdated August 31, 2026
Seres Therapeutics, Inc. logo
Ticker
MCRB:BX
Asset type
Stock
Market cap
$50.8M
Sector
Health Technology
Industry
Biotechnology
Exchange
BX
Currency
CHF

Seres Therapeutics, Inc. MCRB:BX stock context

This page tracks Seres Therapeutics, Inc.'s MCRB:BX listing on BX in CHF for CH, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following MCRB:BX. MCRB:BX is the stock-level entry point for investors researching Seres Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Seres Therapeutics, Inc. is a public company traded under the ticker MCRB in the American market. The company has a market capitalization of approximately $48 million. Seres focuses on developing microbiome-based therapeutics to treat various diseases.

Latest news from Seres Therapeutics, Inc.

All Seres Therapeutics, Inc. news →

Seres Therapeutics, Inc. earnings calls

Research Seres Therapeutics, Inc.

Alternate listings